These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 11700390)

  • 1. The vascular endothelial growth factor (VEGF) signaling pathway: a therapeutic target in patients with hematologic malignancies.
    Giles FJ
    Oncologist; 2001; 6 Suppl 5():32-9. PubMed ID: 11700390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The emerging role of angiogenesis inhibitors in hematologic malignancies.
    Giles FJ
    Oncology (Williston Park); 2002 May; 16(5 Suppl 4):23-9. PubMed ID: 12102577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications.
    Ellis LM; Takahashi Y; Liu W; Shaheen RM
    Oncologist; 2000; 5 Suppl 1():11-5. PubMed ID: 10804085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular endothelial growth factor signaling pathway as an emerging target in hematologic malignancies.
    List AF
    Oncologist; 2001; 6 Suppl 5():24-31. PubMed ID: 11700389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of vascular endothelial growth factor (VEGF) in AIDS-related Kaposi's sarcoma.
    Arastéh K; Hannah A
    Oncologist; 2000; 5 Suppl 1():28-31. PubMed ID: 10804088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications.
    Ferrara N
    Semin Oncol; 2002 Dec; 29(6 Suppl 16):10-4. PubMed ID: 12516033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers.
    Rosen LS
    Cancer Control; 2002; 9(2 Suppl):36-44. PubMed ID: 11965229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiogenesis and angiogenic mediators in haematological malignancies.
    Mangi MH; Newland AC
    Br J Haematol; 2000 Oct; 111(1):43-51. PubMed ID: 11091181
    [No Abstract]   [Full Text] [Related]  

  • 9. VEGF receptor signaling in tumor angiogenesis.
    McMahon G
    Oncologist; 2000; 5 Suppl 1():3-10. PubMed ID: 10804084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors.
    Schlaeppi JM; Wood JM
    Cancer Metastasis Rev; 1999; 18(4):473-81. PubMed ID: 10855790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies.
    Podar K; Anderson KC
    Curr Cancer Drug Targets; 2011 Nov; 11(9):1005-24. PubMed ID: 21933109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of vascular endothelial growth factor-associated tyrosine kinase activity with SU5416 blocks sprouting in the microvascular endothelial cell spheroid model of angiogenesis.
    Haspel HC; Scicli GM; McMahon G; Scicli AG
    Microvasc Res; 2002 May; 63(3):304-15. PubMed ID: 11969307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measuring VEGF-Flk-1 activity and consequences of VEGF-Flk-1 targeting in vivo using intravital microscopy: clinical applications.
    Vajkoczy P; Thurnher A; Hirth KP; Schilling L; Schmiedek P; Ullrich A; Menger MD
    Oncologist; 2000; 5 Suppl 1():16-9. PubMed ID: 10804086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiogenesis inhibition in solid tumors.
    Rosen LS
    Cancer J; 2001; 7 Suppl 3():S120-8. PubMed ID: 11779082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications.
    Podar K; Anderson KC
    Blood; 2005 Feb; 105(4):1383-95. PubMed ID: 15471951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A targeted approach for antiangiogenic therapy of metastatic human colon cancer.
    Ellis LM
    Am Surg; 2003 Jan; 69(1):3-10. PubMed ID: 12575772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors.
    Chung AS; Kowanetz M; Wu X; Zhuang G; Ngu H; Finkle D; Komuves L; Peale F; Ferrara N
    J Pathol; 2012 Aug; 227(4):404-16. PubMed ID: 22611017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of angiogenesis inhibitors in acute myeloid leukemia.
    Fiedler W; Staib P; Kuse R; Dührsen U; Flasshove M; Cavalli F; Hossfeld DK; Berdel WE
    Cancer J; 2001; 7 Suppl 3():S129-33. PubMed ID: 11779083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. von Hippel-Lindau syndrome: target for anti-vascular endothelial growth factor (VEGF) receptor therapy.
    Harris AL
    Oncologist; 2000; 5 Suppl 1():32-6. PubMed ID: 10804089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiogenic and lymphangiogenic molecules in hematological malignancies.
    Orpana A; Salven P
    Leuk Lymphoma; 2002 Feb; 43(2):219-24. PubMed ID: 11999550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.